The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology
Speakers' Bureau - Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).
 
Elizabeth R. Plummer
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Biomarin; Clovis Oncology; Karus Therapeutics; Mission Therapeutics; MSD Oncology; Novartis; Roche/Genentech; Tesaro; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Eisai (Inst); Etherapeutics (Inst); Ipsen (Inst); vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech
 
Emma Jane Dean
Consulting or Advisory Role - Aptus Clinical (Inst); Theradex Ltd
Travel, Accommodations, Expenses - AstraZeneca
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Baxter; Bristol-Myers Squibb; Eisai; Karus Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Celgene
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); e-Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); Roche (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene
 
Alastair Greystoke
No Relationships to Disclose
 
Karin Herbschleb
No Relationships to Disclose
 
Malcolm Ranson
No Relationships to Disclose
 
Jennifer Brown
No Relationships to Disclose
 
Yanqiong Zhang
Employment - Vertex
Stock and Other Ownership Interests - Vertex
 
Sharon Karan
Employment - Intercept Pharmaceuticals; Vertex
Stock and Other Ownership Interests - Vertex
 
John Pollard
Employment - Vertex
Stock and Other Ownership Interests - Vertex
 
Marina S. Penney
Employment - Vertex
Stock and Other Ownership Interests - Vertex
 
Mohammed Asmal
Employment - Bluebird Bio
Stock and Other Ownership Interests - Vertex
 
Scott Z. Fields
Employment - Vertex
Stock and Other Ownership Interests - Vertex
 
Mark R. Middleton
Consulting or Advisory Role - Eisai
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Vertex (Inst)